

 Open access • Posted Content • DOI:10.1101/568121

Production of nonnatural straight-chain amino acid 6-aminocaproate via an artificial iterative carbon-chain-extension cycle — [Source link](#)

Jie Cheng, Tingting Song, Huayu Wang, Xiaohua Zhou ...+4 more authors

Institutions: Chinese Academy of Sciences, Chongqing University, Massachusetts Institute of Technology

Published on: 05 Mar 2019 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Amino acid, Carboxylic acid and Enzyme catalysis

Related papers:

- [Production of nonnatural straight-chain amino acid 6-aminocaproate via an artificial iterative carbon-chain-extension cycle.](#)
- [Synthesis of l- \$\alpha\$ -amino- \$\omega\$ -bromoalkanoic acid for side chain modification](#)
- [Methods and materials for biosynthesizing multifunctional, multivariate molecules via carbon chain modification](#)
- [Scalable and selective \$\beta\$ -hydroxy- \$\alpha\$ -amino acid synthesis catalyzed by promiscuous L-threonine transaldolase ObiH](#)
- [Efficient Synthesis of Enantiopure \$\beta\$ -Amino- \$\gamma\$ -Keto Acids from l-Homoserine](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/production-of-nonnatural-straight-chain-amino-acid-6-qcb94winhi>

1 **Production of nonnatural straight-chain amino acid 6-aminocaproate**
2 **via an artificial iterative carbon-chain-extension cycle**

3
4 **Jie Cheng^{1,2}, Tingting Song¹, Huayu Wang¹, Xiaohua Zhou¹, Michael P. Torrens-**
5 **Spence³, Dan Wang^{1,*}, Jing-Ke Weng^{3,4,*}, Qinhong Wang^{2,*}**

6
7 ¹ Department of Chemical Engineering, School of Chemistry and Chemical Engineering,
8 Chongqing University, Chongqing 401331, P. R. China

9 ² Key Laboratory of Systems Microbial Biotechnology, Tianjin Institute of Industrial
10 Biotechnology, Chinese Academy of Sciences, Tianjin 300308, P. R. China

11 ³ Whitehead Institute for Biomedical Research, 455 Main Street, Cambridge, MA,
12 02142, United States

13 ⁴ Department of Biology, Massachusetts Institute of Technology, Cambridge, MA,
14 United States

15 * Corresponding author: Tel: +86-23-65678926

16 E-mail: dwang@cqu.edu.cn (D. Wang), wang_qh@tib.cas.cn (Q.H. Wang)

17 *E-mail address:* 55 Daxuecheng South Road, Shapingba District, Department of
18 Chemical Engineering, School of Chemistry and Chemical Engineering, Chongqing
19 University, Chongqing, 401331, P. R. China.

20

21

22 Abstract

23 Bioplastics produced from microbial source are promising green alternatives to
24 traditional petrochemical-derived plastics. Nonnatural straight-chain amino acids,
25 especially 5-aminovalerate, 6-aminocaproate and 7-aminoheptanoate are potential
26 monomers for the synthesis of polymeric bioplastics as their primary amine and
27 carboxylic acid are ideal functional groups for polymerization. Previous pathways for
28 5-aminovalerate and 6-aminocaproate biosynthesis in microorganisms are derived from
29 L-lysine catabolism and citric acid cycle, respectively. Here, we show the construction
30 of an artificial iterative carbon-chain-extension cycle in *Escherichia coli* for
31 simultaneous production of a series of nonnatural amino acids with varying chain length.
32 Overexpression of L-lysine α -oxidase in *E. coli* yields 2-keto-6-aminocaproate as a
33 non-native substrate for the artificial iterative carbon-chain-extension cycle. The chain-
34 extended α -ketoacid is subsequently decarboxylated and oxidized by an α -ketoacid
35 decarboxylase and an aldehyde dehydrogenase, respectively, to yield the nonnatural
36 straight-chain amino acid products. The engineered system demonstrated simultaneous
37 *in vitro* production of 99.16 mg/L of 5-aminovalerate, 46.96 mg/L of 6-aminocaproate
38 and 4.78 mg/L of 7-aminoheptanoate after 8 hours of enzyme catalysis starting from 2-
39 keto-6-aminocaproate as the substrate. Furthermore, simultaneous production of 2.15
40 g/L of 5-aminovalerate, 24.12 mg/L of 6-aminocaproate and 4.74 mg/L of 7-
41 aminoheptanoate was achieved in engineered *E. coli*. This work illustrates a promising
42 metabolic-engineering strategy to access other medium-chain organic acids with -NH₂,
43 -SCH₃, -SOCH₃, -SH, -COOH, -COH, or -OH functional groups through carbon-chain-
44 elongation chemistry.

45 **Keywords:** Nonnatural straight chain amino acid, 6-Aminocaproate, Carbon chain
46 elongation, Synthetic biology, Iterative cycle

47

48 **Abbreviations:**

49 **NNSCAA**, Nonnatural straight chain amino acid; **5AVA**, 5-Aminovalerate; **6ACA**, 6-
50 Aminocaproate; **7AHA**, 7-Aminoheptanoate; **RaiP**, L-lysine α oxidase; **LeuA**, α -
51 Isopropylmalate synthase; **LeuA***, LeuA mutants; **LeuA[#]**, LeuA with
52 H97L/S139G/G462D mutations; **LeuB**, 3-Isopropylmalate dehydrogenase; **LeuC**, 3-
53 Isopropylmalate dehydratase; **LeuD**, 3-Isopropylmalate dehydratase; **KivD**, α -
54 Ketoacid decarboxylase; **PadA**, Aldehyde dehydrogenase; **ThDP**, Thiamine
55 diphosphate; **TCEP**, Tris (2-carboxyethyl) phosphine; **KPB**, Potassium phosphate
56 buffer; **LC-MS**, Liquid chromatography-mass spectrometry; **SDS-PAGE**, Sodium
57 dodecyl sulfate polyacrylamide gel electrophoresis; **4AAP**, 4-Aminoantipyrine

58

59

60

61 1. Introduction

62 Microbial polyimide bioplastics present a class of green materials with broad
63 applications in many downstream industries, and can potentially replace the traditional
64 petrochemical-derived polymers. Consequently, platform chemicals containing suitable
65 functional groups necessary for polyimide polymerization have attracted significant
66 attention as targets for metabolic engineering. These compounds include diamines such
67 as putrescine (Del Rio et al., 2018) and cadaverine (Kim et al., 2018), amino acids such
68 as lysine (Borri et al., 2018) and glutamate, organic acids such as succinate (Jantama et
69 al., 2008) and lactate (Pang et al., 2010), diols such as butanediol and hexanediol
70 (Muller et al., 2010). Nonnatural straight-chain amino acids (NNSCAAs), especially 5-
71 aminovalerate (5AVA) and 6-aminocaproate (6ACA) are important platform chemicals
72 for the synthesis of polyimides, which are widely used as raw materials for automobile
73 parts, clothes, backpacks and disposable goods such as nylon 5, nylon 6 and nylon 5,6
74 (Haushalter et al., 2017). In addition to its utility in bioplastics, 6ACA was also
75 implicated to promote blood clotting, suggesting potential applications as an
76 antifibrinolytic agent (Lu et al., 2015; Schou-Pedersen et al., 2015). Whereas 5AVA
77 biosynthesis is a viable approach for industrial production, effective methods to
78 biosynthesize other NNSCAAs at scale has yet to be established (Jorge et al., 2017;
79 Turk et al., 2016). Biosynthesis of 6ACA was first demonstrated to occur through the
80 condensation of acetyl-CoA and succinyl-CoA (Turk et al., 2016). The second
81 biosynthetic route utilizes α -ketoadipate as the starter molecule, which is chain-
82 extended by (homo)₁₋₃aconitate synthase (AksA), (homo)₁₋₃aconitate isomerase
83 complex (AksD, AksE), iso(homo)₁₋₃citrate dehydrogenase (AksF) to give the
84 intermediate α -ketopimelate (AKP). AKP is decarboxylated and transaminated to yield

85 6ACA (Chae et al., 2017). The precursors of the two pathways are all derived from the
86 tricarboxylic acid (TCA) cycle which are scarce in cells. With inadequate
87 transamination efficiency previously recognized (Zhang et al., 2010), the final titer
88 achieved by Turk *et al.* was only 160 mg/L (Jorge et al., 2017; Turk et al., 2016).

89 L-lysine is the second most-produced amino acid worldwide after glutamate.
90 Currently, L-lysine is mainly produced through microbial fermentation, and is
91 commonly used as an additive to poultry and swine feed (Wang et al., 2016). Annual
92 world L-lysine production is estimated to exceed 2.5 million tons by 2020 (Vassilev et
93 al., 2018). Due to the market competition in industrial capacity and demand, the price
94 of L-lysine as a commodity chemical has dropped significantly in recent years (Xu et
95 al., 2018). As a result, developing high-value chemicals derived from L-lysine presents
96 an emerging opportunity in the field of metabolic engineering (Cheng et al., 2018a).
97 Novel L-lysine-derived products may contribute to an environmentally friendly
98 chemical industry (Hoffmann et al., 2018; Sgobba et al., 2018).

99 Nonpolymeric carbon-chain-extension pathways occur broadly in many primary
100 metabolism pathways for the synthesis of rare sugars (Yang et al., 2017), α -ketoacids
101 (Sonderby et al., 2010; Wen et al., 2013), fatty acids (Wu et al., 2014), and as well as
102 several specialized metabolic pathways for the synthesis of polyketides (Gokhale et al.,
103 2007; Miyanaga, 2017) and terpenoids (Gronenberg et al., 2013; Yu et al., 2012). The
104 chain extension of the aforementioned metabolic systems generally consists of a series
105 of condensation, dehydration and reduction reactions (Chandran et al., 2011; Katz and
106 Donadio, 1993; Textor et al., 2007). The first carbon-chain-extension step of the
107 pathway is catalyzed by a C-acetyltransferase, such as the citramalate synthase in the
108 citramalate pathway (Drevland et al., 2007), the citrate synthase in the TCA (Harder et
109 al., 2018), the α -isopropylmalate synthase (LeuA) in the leucine pathway (Hunter and

110 Parker, 2014), the homocitrate synthase in the L-lysine α -aminoadipate pathway
111 (Zabriskie and Jackson, 2000), the methylthioalkylmalate synthase (MAM) in the
112 glucosinolate pathway (Mirza et al., 2016) and the (Homo)₁₋₃aconitate synthase (AksA)
113 in the biosynthetic pathway of coenzyme B (Howell et al., 1998). Amongst various C-
114 acetyltransferases, LeuA is paid much more attention. In its native pathway, LeuA
115 catalyzes the condensation of acetyl-CoA and α -ketoisovalerate in the first step of
116 leucine biosynthesis (Shen and Liao, 2011). LeuA could also catalyze the condensation
117 of acetyl-CoA and α -ketobutyrate to produce α -ketovalerate as a precursor of the non-
118 natural amino acid (Shen and Liao, 2008). Overexpression of LeuABCD, α -ketoacid
119 decarboxylase (KivD) and alcohol dehydrogenase (ADH6) in a modified threonine-
120 overproduction strain of *Escherichia coli* (*E. coli*) ATCC98082/ThrABC-TdcB-
121 IlvGMCD led to the production of (*S*)-3-methyl-1-pentanol with a final titer of 6.5 mg/L
122 (Zhang et al., 2008). However, several mutants derived from LeuA exhibit interesting
123 substrate promiscuity and catalyzes flexibility, which we use LeuA* to refer to (Shen
124 and Liao, 2008; Umbarger, 1978). LeuA* displays an enhanced degree of substrate
125 promiscuity and is capable of catalyzing the condensation reaction on multiple α -
126 ketoacid substrates (Shen and Liao, 2008). A mutant with LeuA* G462D to replace the
127 LeuA in engineered strain ATCC98082/ThrABC-TdcB-IlvGMCD-LeuA*BCD-KIVD-
128 ADH6 led to an improved titer of (*S*)-3-methyl-1-pentanol at 40.8 mg/L. Another
129 LeuA* G462D/S139G mutant could improve the titer of 1-pentanol to 204.7 mg/L
130 (Zhang et al., 2008). Nevertheless, only limited functional groups have been
131 successfully introduced into ketoacid elongation pathway.

132 In this study, we explore the use of an L-lysine-derived α -ketoacid with -NH₂
133 functional group as a substrate for LeuABCD-catalyzed carbon-chain-extensions. We
134 build an artificial iterative carbon-chain-extension cycle for NNSCAA biosynthesis

135 from L-lysine as seen in Fig. 1. We demonstrate that NNSCAAs of C5, C6 and C7 could
136 be simultaneously produced in engineered *E. coli* strain.

137

138 **2. Material and methods**

139 **2.1 Strains, plasmids and primers used in this study**

140 All the strains and plasmids involved are listed in Table S1. Primers used in this
141 study are listed in Table S2. *E. coli* BL21(DE3) was used for the production of
142 NNSCAAs. *E. coli* DH5 α was used for plasmid amplification. The L-lysine α oxidase
143 gene (*raiP*) from *Scomber japonicas* (GenBank Accession No. MG423617) was
144 amplified from pCJ01 (Cheng et al., 2018b). The coding regions of *leuA*, 3-
145 isopropylmalate dehydrogenase gene (*leuB*), 3-isopropylmalate dehydratase gene
146 (*leuC*), 3-isopropylmalate dehydratase gene (*leuD*) and aldehyde dehydrogenase gene
147 (*padA*) were amplified from *E. coli* MG1655 by PCR using appropriate primers (Table
148 S2). The α -ketoacid decarboxylase gene (*kivD*) from *Lactococcus lactis* (GenBank
149 Accession No. 51870501) was chemically and optimally synthesized by Genewiz Co.
150 (Suzhou, China) (Li et al., 2011). In order to establish and validate the whole
151 biosynthetic pathway, the *leuA* and *leuBCD* genes from *E. coli* MG1655 were
152 constructed in a single operon in transcriptional order *leuA-leuB-leuC-leuD*, and then
153 the engineered pZA22-*leuA-leuB-leuC-leuD* was produced, also named as pIVC03.
154 LeuA was replaced by LeuA[#] (LeuA*, LeuA with H97L/S139G/G462D mutations) to
155 form the engineered pZA22-*leuA[#]-leuB-leuC-leuD*, also named as pIVC04. The *raiP*
156 from *Scomber japonicus*, *kivD* from *Lactococcus lactis* and *padA* from *E. coli* MG1655
157 were constructed in another operon in transcriptional order *raiP-kivD-padA*. The
158 engineered pET21a-*raiP-kivD-padA* was produced, also named as pETaRKP.

159 BL21(DE3) was transformed with the plasmid pIVC03 or pIVC04 and pETaRKP,
160 resulting in strain CJ03 or CJ04.

161 **2.2 Fermentation procedures**

162 The fermentation media were developed for evaluating strain's potential for
163 NNSCAAs production. The medium was supplemented by 10 g/L NaCl, 10 g/L
164 tryptone, 5 g/L yeast extract, 1.0 mM MgSO₄, 0.5 mM thiamine diphosphate (ThDP)
165 (Chen et al., 2017). For NNSCAAs production, a single colony of the desired strain was
166 cultivated for 12 h at 37 °C and 250 RPM in 2 mL LB medium supplemented with
167 appropriate antibiotics. This starter culture were then transferred into 40 mL of
168 fermentation medium supplemented with appropriate antibiotics, 1.0 mM MgSO₄ and
169 0.5 mM ThDP at 37 °C with 250 RPM orbital shaking at a starting optical density at
170 600 nm (OD₆₀₀) of 0.1 in a 250 mL flask. After an OD₆₀₀ of 0.6 has been reached, 0.5
171 mM of IPTG and 5 g/L of L-lysine were added. Flasks were then incubated at 30 °C.

172 **2.3 Protein expression and purification**

173 BL21(DE3) harboring pETaraiP, pETaleuA, pETaleuB, pETaleuC, pETaleuD,
174 pETbkivD, pETapadA and various mutants of LeuA were screened on selective LB agar
175 plates supplemented with 100 µg/mL ampicillin, respectively. A positive clone was
176 inoculated in 2 mL LB at 37 °C and 250 RPM for 12 h. 2 mL of seed cultures were
177 transferred into 200 mL LB containing 100 µg/mL ampicillin. At an OD₆₀₀ of 0.6, the
178 cells were induced by 0.5 mM IPTG and incubated at 20 °C and 250 RPM for 16 h. The
179 cells were collected by centrifugation at 10,000 RPM for 5 min and washed twice with
180 potassium phosphate buffer (KPB, 50 mM, pH 8.0). The cells were resuspended and
181 disrupted by sonication in 50 mM KPB and 2 mM tris (2-carboxyethyl) phosphine

182 (TCEP) in an ice bath. The enzymes were purified by AKTA Purifier 10 using a Ni-
183 NTA column (GE Healthcare, USA). The purified enzymes were desalted and
184 exchanged into storage buffer (50 mM KPB, 1.0 mM MgSO₄, 2 mM TCEP, 10%
185 glycerol, pH 8.0) (Fan et al., 2018). The purified enzymes were stored at -80 °C. The
186 UV absorbance at 280 nm was mensurated as the protein concentration by SpectraMax
187 M2^e (Molecular Devices, American) (Annamalai et al., 2011; Zhang et al., 2008).
188 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to
189 analyze the purity of purified enzymes with a 12 % acrylamide gel (Tani et al., 2015a).

190 **2.4 Enzyme assay**

191 RaiP activity was surveyed by determining hydrogen peroxide produced as
192 Cheng *et al.* reported (Cheng et al., 2018b). The reaction buffer embodied 50 mM KPB
193 (pH 8.0), 30.0 mM L-lysine, 0.5 mM 4-aminoantipyrine (4AAP), 10 units/ml catalase
194 and 26.5 mM phenol (Muramatsu et al., 2006). The standard reaction mixture embodied
195 8 µg RaiP and 180 µL reaction buffer. The reaction was conducted at 30 °C and stopped
196 by adding 10 µL of 10 M HCl. 10 µL of 10 M NaOH was added for neutralization of
197 the reaction, and then Quinoneimine dye formed was measured at 505 nm per 5 minutes
198 using SpectraMax M2^e (Molecular Devices, American) (Job et al., 2002; Tani et al.,
199 2015a; Tani et al., 2015b). One unit of enzyme activity was defined as the amount of
200 enzyme that catalyzes 1 µmol of hydrogen peroxide produced per minute.

201 LeuA and LeuA* activities were assayed by measuring CoASH produced (Zhang
202 et al., 2008). The assay mixture contained 50 mM KPB (pH 8.0), 0.03 µM acetyl-CoA,
203 30.0 mM L-lysine, 2.0 µM RaiP and 8 µg LeuA or LeuA* with a total volume of 205
204 µL. The reaction was performed at 37 °C and stopped by adding 10 µL of 10 M HCl.
205 10 µL of 10 M NaOH was added for neutralization of the reaction, then 50 µL of a fresh

206 3.0 mM solution of 5,5'-Dithio-Bis (2 Nitrobenzoic Acid) (DTNB) in 50 mM KPB was
207 added, and the yellow color product was determined at 412 nm using SpectraMax M2^e
208 (Molecular Devices, American). One unit of enzyme activity was defined as the amount
209 of enzyme that catalyzes 1.0 μ mol of CoASH produced per minute. There were no other
210 intermediates as substrates, so the enzyme activities of LeuB, LeuC, LeuD, KivD and
211 PadA could not be detected.

212 **2.5 *In vitro* 6ACA synthesis**

213 To measure the rate of the conversion of L-lysine into 6ACA by purified enzyme,
214 an assay mixture was established, which contained 800 μ L of 50 mM KPB (pH 8.0),
215 2.5 mM L-lysine, 2.0 mM acetyl-CoA, 0.5 mM ThDP, 1.0 mM NAD⁺, 1.0 mM TCEP.
216 All assays were started with the addition of the different purified enzyme dosage and
217 incubating at 37 °C. 400 μ L samples were withdrawn at designated time points and
218 inactivated at 75 °C for 10 min, and then centrifuged at 10000 RPM for 10 min to
219 remove cells for further metabolite analysis.

220 **2.6 Analytical methods**

221 The optical density of the various *E. coli* cultures was detected using a UV/visible
222 spectrophotometer (Ultrospec TM 2100 pro, GE Healthcare, UK). The quantification
223 of L-lysine, 5AVA, 6ACA and 7AHA were conducted by high performance liquid
224 chromatography (HPLC) using a 1260 system (Agilent Co., Ltd, CA, USA) with an
225 Agilent Eclipse XDB-C18 column (4.6 mm \times 150 mm \times 5 μ m). For detection of L-
226 lysine, 5AVA, 6ACA and 7AHA, 360 μ L of culture centrifuged was derived with phenyl
227 isothiocyanate (PITC) (Cheng et al., 2018b; Zheng et al., 2015). The operating
228 conditions were performed as 1.0 mL/min, column temperature 40 °C, wavelength 254

229 nm and analysis time 55 min. The gradient program was shown in Table S3. For liquid
230 chromatography-mass spectrometry (LC-MS) identification of 5AVA, 6ACA and
231 7AHA, exact mass spectra were explored with a Bruker micrOTOF-Q II mass
232 spectrometer using the time of flight (TOF) technique, equipped with an ESI source
233 operating in negative mode (Burker Co., Ltd, USA). The product was verified by LC-
234 MS (Fig. 3). The approximate retention times of 5AVA, 6ACA, 7-aminoheptanoate
235 (7AHA) and L-lysine were 7.2 min, 9.4 min, 11.8 min and 25.6 min, respectively (Fig.
236 3A). LC-MS results of the 5AVA, 6ACA and 7AHA showed that the $[M-H]^-$ of 5AVA,
237 6ACA and 7AHA were 251.0801 (Fig. 3B), 265.1012 (Fig. 3C) and 279.1175 (Fig. 3D),
238 respectively, which were as the same as that of the 5AVA, 6ACA and 7AHA standards.
239

240 **3. Results and discussion**

241 **3.1 Construction of a L-lysine derived artificial iterative carbon-chain-extension** 242 **cycle *in vitro***

243 To explore the feasibility of a RaiP-LeuABCD-KivD-PadA pathway, the necessary
244 enzymes were expressed, purified and assayed against L-lysine for NNSCAAS
245 synthesis. The purity of recombinant RaiP, LeuA, LeuA*, LeuB, LeuC, LeuD, KivD
246 and PadA carrying a C-terminal His-tag in *E. coli* BL21(DE3) was assessed by SDS-
247 PAGE shown in Fig. S1. The sizes of the recombinant proteins were 55, 52, 38, 50, 21,
248 57 and 52 kDa respectively, which were consistent with the predicted size of RaiP, LeuA,
249 LeuB, LeuC, LeuD, KivD and PadA proteins. The SDS-PAGE analysis of various LeuA
250 mutants were shown in Fig. S3.

251 The activities of various LeuA mutants (LeuA*) were shown in Fig. 2. LeuA
252 exhibited low activity toward 2-keto-6-aminocaproate, whereas LeuA mutations

253 (H97A/G462D, H97G/G462D, H97L/G462D, S139G/G462D and S139I/G462D)
254 displayed higher activities. The LeuA H97L/S139G/G462D (LeuA[#]) showed highest
255 activity shown in Table 1. The activities of RaiP toward L-lysine and LeuA[#] toward 2-
256 keto-6-aminocaproate in the crude extracts were 5.14 and 0.0012 units/mg, respectively.
257 141-fold purification factor and 58.62% yields of RaiP were obtained, with specific
258 activity of 724.88 units/mg shown in Table 1. 25-fold purification factor and 13.33%
259 yields of LeuA[#] were achieved, with specific activity of 0.03 units/mg. RaiP showed a
260 K_m value of 2.945 mM, a K_{cat} value of 710.587 s^{-1} and a K_{cat}/K_m value of 241292 $M^{-1}s^{-1}$
261 ¹ when L-lysine is used as the substrate. LeuA[#] displays a K_m value of 23.450 mM, a
262 K_{cat} value of 1.321 s^{-1} and a K_{cat}/K_m value of 26.344 $M^{-1}s^{-1}$ with 2-keto-6-aminocaproate
263 used as the substrate shown in Table 2.

264 Amano *et al.* and Arinbasarova *et al.* have previously characterized the
265 recombinant enzyme of RaiP from *Trichoderma viride* (Amano *et al.*, 2015;
266 Arinbasarova *et al.*, 2012). However, the reported specific activities of the purified
267 enzyme was just 80 or 90 U/mg in the previous studies, which are about 11% of the
268 specific activity we measured in this study. It is likely that a fraction of the enzyme
269 might have lost its activity in the process of ammonium sulfate precipitation and two-
270 step column purification in the previous studies (Tani *et al.*, 2015b). Zhang *et al.*
271 reported that the LeuA G462D mutant displays a low K_{cat} of 0.018 s^{-1} for (S)-2-keto-3-
272 methylvalerate (Zhang *et al.*, 2008). However, the LeuA S139G/G462D mutant exhibits
273 a much higher K_{cat} of 0.12 s^{-1} for (S)-2-keto-3-methylvalerate. We therefore introduced
274 an additional mutations at His97 in LeuA[#]. Interestingly, LeuA[#] shows significantly
275 improved K_{cat} of 1.32 s^{-1} for 2-keto-6-aminocaproate shown in Table 2.

276 **3.2 Building a nonnatural iterative cycle for NNSCAA biosynthesis *in vitro***

277 Upon the successful engineering of LeuA, we designed a novel NNSCAA
278 biosynthetic pathway by combining a “+1” carbon-chain-extension pathway with
279 subsequent α -ketoacid decarboxylation and oxidation. The promiscuity of various LeuA
280 mutants was explored, which resulted in an iterative cycle for the production of a series
281 of L-lysine-derived products with different chain lengths (Fig. 6A and Fig. 6B). The
282 titer of total NNSCAAs was 65.92 mg/L after a reaction time of 4 h with enzyme
283 concentration of RaiP, LeuA[#], LeuB, LeuC, LeuD, KivD and PadA setting at 1.0, 20.0,
284 4.0, 2.0, 2.0, 5.0 and 2.0 μ M, respectively. The distribution of 5AVA, 6ACA and 7AHA
285 was 24.0:5.2:1. As could be seen in Fig. 6, with a prolonged reaction time of 8 h, the
286 titer of total NNSCAAs reached 151.28 mg/L, and the distribution of 5AVA, 6ACA and
287 7AHA was 19.2:9.1:1. The identity of the products were verified by LC-MS as shown
288 in Fig. 3.

289 NNSCAAs, especially 5AVA, 6ACA and 7AHA, are important platform chemicals
290 for polyamides synthesis. To our knowledge, simultaneous production of NNSCAAs of
291 various chain length has not been demonstrated in any microbial host. Specific
292 pathways for the production of 5AVA or 6ACA have been developed recently (Cheng
293 et al., 2018b; Turk et al., 2016). The precursors are derived from L-lysine catabolism
294 and TCA cycle, respectively. The engineered *Corynebacterium glutamicum* strain
295 expressing *deta*-aminovaleramidase gene as an operon under a synthetic H₃₆ promoter
296 reportedly produces 5AVA at 33.1 g/L (Shin et al., 2016). 5AVA could be obtained at a
297 higher titer of 63.2 g/L by overexpressing an L-lysine-specific permease (Li et al., 2016).
298 As the transamination activity is limiting (Zhang et al., 2010), the final titer of 6ACA
299 achieved in Turk *et al.*'s study was only 160 mg/L (Jorge et al., 2017; Turk et al., 2016).
300 In our work, we aimed to develop a strategy to simultaneously produce C5, C6 and C7

301 NNSCAAs from L-lysine. To do this, we explored the promiscuity of LeuA mutants
302 towards L-lysine-derived α -ketoacids with amino functional group, which is
303 exemplified by LeuA[#] that can utilize primary amines such as 2-keto-6-aminocaproate
304 and 2-keto-7-aminoheptanoate as substrate. The malleability of the LeuABCD pathway
305 remains to be further explored, as untargeted metabolomics of LeuA* expression *in*
306 *vivo* may identify additional substrates. Furthermore, directed evolution of LeuA or
307 LeuA* may further broaden substrate profile. In *Brassicaceae* plants,
308 Methylthioalkylmalate synthases are evolutionary derived from an ancestral LeuA and
309 catalyze carbon-chain-extension pathway in the biosynthesis of glucosinolates (de
310 Kraker and Gershenzon, 2011; Mirza et al., 2016). The recruitment of LeuA for plant
311 specialized metabolism suggests that the C-acetyltransferase family proteins can be
312 further evolved to arrive at desirable activities starting from ancestral promiscuous
313 activities (Weng and Noel, 2012).

314 **3.3 Dependence of 6ACA productivity on the supply of coenzyme**

315 In this artificial iterative cycle pathway, NAD⁺ is a key coenzyme for LeuB.
316 Moreover, KivD and PadA catalyze the conversion of 2-keto-7-aminoheptanoate to
317 6ACA, which requires coenzymes ThDP and NAD⁺, respectively (Fig. 1). To improve
318 the production of 6ACA, the concentration of NAD⁺ was optimized. Fig. 5A shows the
319 production of 6ACA with varying concentrations of NAD⁺ at pH 8.0 for 8 h. NAD⁺
320 concentration affects the production of 6ACA shown in Fig. 5A. This multi-enzyme
321 cascade system requires NAD⁺ addition to produce 6ACA. When 0.2 mM NAD⁺ was
322 added, the titer of 6ACA was 21.24 mg/L. Increasing concentration of NAD⁺ led to
323 increase titer of 6ACA production. Notably, the concentration of 6ACA increased to
324 46.96 mg/L with 1 mM NAD⁺. Hence, 1 mM of NAD⁺ was set as the optimal dosage.

325 The effect of ThDP, the coenzyme of KivD, was also investigated in this work. The
326 results were shown in Fig. 5B. Varying concentrations of ThDP at pH 8.0 for 8 h was
327 adopted to facilitate the catalysis. The concentration of ThDP affects 6ACA production
328 (Fig. 5B). Without ThDP addition, no 6ACA was produced in this multi-enzyme
329 cascade system. When 0.1 mM ThDP was added, the titer of 6ACA was 20.64 mg/L.
330 Notably, the concentration of 6ACA increased markedly to 46.96 mg/L at 0.5 mM ThDP
331 addition. Consequently, the 0.5 mM of ThDP was set as the optimal dosage.

332 **3.4 The confirmation of the rate-limiting enzyme in this artificial iterative cycle**

333 In our initially assembled artificial iterative cycle, 6ACA titer was low (6.68 mg/L),
334 as seen in Fig. 3A. To further improve the titer, a titration experiment was performed
335 with different concentrations of enzymes. We varied the concentration of RaiP, LeuB,
336 LeuC, LeuD, KivD and PadA from 1.0 to 10.0 μ M, while the concentration of LeuA*
337 was varied from 1.0 to 20.0 μ M. Concentration of 1.0 μ M was chosen for the other
338 enzymes. No significant change in the titer of 6ACA was observed with the increased
339 concentration of RaiP. Increasing the concentrations of LeuA[#] to a proper range led to
340 a 3-5 folds increase (6.68 mg/L to 30.18 mg/L) in the titer of 6ACA. When the
341 concentration of LeuA[#] was 20.0 μ M, 6ACA reached the highest concentration of 30.18
342 mg/L shown in Fig. 4. This result suggests that LeuA[#] is a rate-limiting enzyme in the
343 system, consistent with the previous findings from the iterative nonnatural alcohol
344 system (Zhang et al., 2008). Increasing concentrations of LeuB, LeuC, LeuD, KivD and
345 PadA within a specific range resulted in only a modest increase in the titer of 6ACA.
346 No further titer improvement was observed when the enzyme concentrations reached
347 2.0 μ M for LeuC, LeuD and PadA, 4.0 μ M for LeuB, whereas 5.0 μ M of KivD inhibited
348 6ACA production. The optimal molar ratio of RaiP: LeuA[#]:LeuB: LeuC: LeuD: KivD:

349 PadA was determined as 1:20:4:2:2:5:2 in this artificial iterative pathway, which was
350 inferred from the titration studies, as seen in Fig. 4.

351 **3.5 Assembling a nonnatural NNSCAA biosynthetic pathway in *E. coli***

352 To the best of our knowledge, 6ACA is a nonnatural specialty chemical that could
353 not be directly biosynthesized by any microorganism naturally. Based on the enzyme
354 catalysis result obtained *in vitro*, we sought to build this artificial iterative cycle
355 metabolic pathway in *E. coli* BL21 (DE3) to produce 6ACA by expressing seven
356 enzymes (RaiP, LeuA[#], LeuB, LeuC, LeuD, KivD and PadA), as seen in Fig. 1. The
357 resulted engineered *E. coli* strain produces total NNSCAAs at a titer of 2.18 g/L from
358 L-lysine. After 36 h of aerobic cultivation, there was no accumulation of 6ACA in the
359 control strain. Whereas the engineered strain produced 6ACA with a peak concentration
360 of 24.12 mg/L at 36 h shown in Fig. 7. The successful assembly of this iterative pathway
361 in *E. coli* validates the *in vitro* pathway design for producing L-lysine-derived
362 NNSCAAs.

363 Metabolic engineering of L-leucine biosynthesis using LeuABCD has been
364 thoroughly explored in *E. coli* (Shen and Liao, 2008; Xiong et al., 2012). Further
365 exploitation of LeuA for the production of longer-chain α -ketoacid and alcohols from
366 branched-chain amino acids was also demonstrated recently (Zhang et al., 2008). The
367 resulting strains produced 6.5 mg/L of 3-methyl-1-pentanol, 17.4 mg/L of 1-hexanol
368 and 22.0 mg/L of 5-methyl-1-heptanol, respectively (Zhang et al., 2008). Connor *et al.*
369 showed that 800 mg/L of 3-methyl-1-butanol could be produced via carbon-chain-
370 extension pathway (Connor and Liao, 2008). Atsumi *et al.* reported that 44.4 mg/L of
371 1-butanol could be achieved via carbon-chain-extension pathway (Atsumi et al., 2008).
372 In this work, we utilize the L-lysine-derivative 2-keto-6-aminocaproate as substrate for

373 LeuA^{#BCD}, therefore broadening the known substrate profile to include terminal-
374 amino-group-containing α -ketoacids. Metabolic engineering of 6ACA production was
375 previously attempted in the strain eAKP-744 (Turk et al., 2016). However, the reported
376 strategy was bottlenecked at the transamination step (Turk et al., 2016; Zhang et al.,
377 2010). The production of 6ACA in the artificial iterative cycle developed in our study
378 circumvents the transamination step, therefore greatly improves the efficiency of the
379 whole process. We anticipate that the efficiency of this NNSCAA biosynthetic pathway
380 can be further improved by optimizing various components of the system.

381 The synthetic “+1” carbon-chain-extension pathway with α -ketoacids as substrates
382 has been widely exploited to produce chain-elongated alcohols and acids (Atsumi et al.,
383 2008; Marcheschi et al., 2012; Zhang et al., 2008). The carbon-carbon condensation
384 reaction catalyzed by LeuA follows the Felkin-Anh model for nucleophilic attack on a
385 carbonyl (Benjamin and Collins, 1973; Cherest et al., 1968; Marcheschi et al., 2012).
386 However, previous studies were based on α -ketoacids substrates without R groups and
387 the reactions were not iterative. Quantum mechanical calculation predicts that different
388 R groups containing -NH₂, -SCH₃, -SOCH₃, -SH, -COOH, -COH or -OH would not
389 significantly impact the barrier for carbon-chain-extension reaction (Felnagle et al.,
390 2012; Marcheschi et al., 2012). Howell *et al.* have reported that *aksA* in *Methanococcus*
391 *janaschii* is analogous to *leuA* in *E. coli* (Howell et al., 2000). It is reported that the R
392 group of AksA includes -COOH. α -Ketoglutarate could be converted into α -
393 ketoglutarate, α -ketoglutarate and α -ketoglutarate one after another in *methanoarchaea*
394 by overexpressing AksADEF (Howell et al., 2000; Howell et al., 1998). While R group
395 of LeuA expected here is -NH₂, the sequence identity between LeuA and AksA is 42%,
396 as seen in Fig. S4. Several key residues at the LeuA active site have been verified to
397 play essential role in controlling the pocket size and hence substrate specificity, in

398 particular, H97, S139 and G462 shown in Fig. S2 (Chen et al., 2017; Xiong et al., 2012).
399 The natural substrates of LeuA are 2-ketoisovalerate and 2-ketobutyrate (Shen and Liao,
400 2008). In this study, our engineered *E. coli* strain could use 2-keto-6-aminocaproate as
401 the alternative substrate to simultaneously produce 5AVA, 6ACA and 7AHA from L-
402 lysine with a titer of total at 2.18 g/L, as seen in Fig. 7.

403

404 **4. Conclusion**

405 In summary, we devised a novel strategy to biosynthesize NNSCAAs with
406 different carbon lengths simultaneously in engineered *E. coli*. This work provides a
407 sustainable route for industrial NNSCAA production from renewable feedstocks using
408 metabolic engineering. By coupling new metabolic pathway design and condition
409 optimization, 99.15 mg/L and 46.96 mg/L of 5AVA and 6ACA could be produced *in*
410 *vitro*, as seen in Fig. 3B and Fig. 6, respectively. Furthermore, production of 4.78 g/L
411 7AHA could be demonstrated for the first time, which could be used to synthesize new
412 polyurethane nylon 7. LeuA[#] is the rate-limiting enzyme in this artificial iterative
413 reaction, which may be further improved by directed evolution approach in the future.
414 Our success in metabolic engineering the production of 6-aminocaproate and other
415 NNSCAAs via the artificial iterative carbon-chain-extension cycle suggests that similar
416 strategies could be developed to produce other medium-chain-length acids with -NH₂,
417 -SCH₃, -SOCH₃, -SH, -COOH, -COH or -OH functional groups.

418

419 **Notes**

420 The authors declare no competing financial interest.

421

422 **Acknowledgements**

423 This research was supported by the Fundamental Research Funds for the Central
424 Universities (Project No. 106112017CDJXFLX0014, 2018CDQYHG0010), the
425 Science and Technology Support Program of Tianjin, China (15PTCYSY00020), the
426 Research Equipment Program of Chinese Academy of Sciences (YJKYYQ20170023),
427 the Key Laboratory of Systems Microbial Biotechnology, Tianjin Institute of Industrial
428 Biotechnology, Chinese Academy of Sciences, and the Henan Provincial Science and
429 technology Open cooperation projects (162106000014). This work is also partially
430 supported by Open Funding Project of the State Key Laboratory of Bioreactor
431 Engineering, Shanghai, China.

432

433 References

- 434 Amano, M., Mizuguchi, H., Sano, T., Kondo, H., Shinyashiki, K., Inagaki, J., Tamura, T., Kawaguchi, T.,
435 Kusakabe, H., Imada, K., Inagaki, K., 2015. Recombinant expression, molecular characterization
436 and crystal structure of antitumor enzyme, L-Lysine α -oxidase from *Trichoderma viride*. *J.*
437 *Biochem.* 157, 549-559.
- 438 Annamalai, N., Veeramuthu Rajeswari, M., Vijayalakshmi, S., Balasubramanian, T., 2011. Purification and
439 characterization of chitinase from *Alcaligenes faecalis* AU02 by utilizing marine wastes and its
440 antioxidant activity. *Ann Microbiol.* 61, 801-807.
- 441 Arinbasarova, A. Y., Ashin, V. V., Makrushin, K. V., Medentsev, A. G., Lukasheva, E. V., Berezov, T. T., 2012.
442 Isolation and properties of L-lysine- α -oxidase from the fungus *Trichoderma cf. aureoviride*
443 RIFAI VKM F-4268D. *Microbiology.* 81, 549-554.
- 444 Atsumi, S., Hanai, T., Liao, J. C., 2008. Non-fermentative pathways for synthesis of branched-chain higher
445 alcohols as biofuels. *Nature.* 451, 86-9.
- 446 Benjamin, B. M., Collins, C. J., 1973. Orbital factors and asymmetric induction. *J. Am. Chem. Soc.* 95,
447 6146-6147.
- 448 Borri, C., Centi, S., Ratto, F., Pini, R., 2018. Polylysine as a functional biopolymer to couple gold nanorods
449 to tumor-tropic cells. *J Nanobiotechnology.* 16, 50.
- 450 Chae, T. U., Ko, Y. S., Hwang, K. S., Lee, S. Y., 2017. Metabolic engineering of *Escherichia coli* for the
451 production of four-, five- and six-carbon lactams. *Metab Eng.* 41, 82-91.
- 452 Chandran, S. S., Kealey, J. T., Reeves, C. D., 2011. Microbial production of isoprenoids. *Process*
453 *Biochemistry.* 46, 1703-1710.
- 454 Chen, G. S., Siao, S. W., Shen, C. R., 2017. Saturated mutagenesis of ketoisovalerate decarboxylase V461
455 enabled specific synthesis of 1-pentanol via the ketoacid elongation cycle. *Sci. Rep.* 7, 11284.
- 456 Cheng, J., Chen, P., Song, A., Wang, D., Wang, Q., 2018a. Expanding lysine industry: industrial
457 biomanufacturing of lysine and its derivatives. *J. Ind. Microbiol. Biotechnol.* 45, 719-734.
- 458 Cheng, J., Zhang, Y., Huang, M., Chen, P., Zhou, X., Wang, D., Wang, Q., 2018b. Enhanced 5-
459 aminovalerate production in *Escherichia coli* from L-lysine with ethanol and hydrogen peroxide
460 addition. *J. Chem. Technol. Biotechnol.* 93, 3492-3501.
- 461 Cherest, M., Felkin, H., Prudent, N., 1968. Torsional strain involving partial bonds. The stereochemistry
462 of the lithium aluminium hydride reduction of some simple open-chain ketones. *Tetrahedron*
463 *Letters.* 2199-2204.

- 464 Connor, M. R., Liao, J. C., 2008. Engineering of an *Escherichia coli* strain for the production of 3-methyl-
465 1-butanol. *Appl. Environ. Microbiol.* 74, 5769-75.
- 466 de Kraker, J. W., Gershenzon, J., 2011. From amino acid to glucosinolate biosynthesis: protein sequence
467 changes in the evolution of methylthioalkylmalate synthase in *Arabidopsis*. *Plant Cell.* 23, 38-
468 53.
- 469 Del Rio, B., Alvarez-Sieiro, P., Redruello, B., Martin, M. C., Fernandez, M., Ladero, V., Alvarez, M. A., 2018.
470 *Lactobacillus rossiae* strain isolated from sourdough produces putrescine from arginine. *Sci.*
471 *Rep.* 8, 3989.
- 472 Drevland, R. M., Waheed, A., Graham, D. E., 2007. Enzymology and evolution of the pyruvate pathway
473 to 2-oxobutyrate in *Methanocaldococcus jannaschii*. *J. Bacteriol.* 189, 4391-400.
- 474 Fan, L., Wang, Y., Tuyishime, P., Gao, N., Li, Q., Zheng, P., Sun, J., Ma, Y., 2018. Engineering Artificial Fusion
475 Proteins for Enhanced Methanol Bioconversion. *Chembiochem.* 19, 2465-2471.
- 476 Felnagle, E. A., Chaubey, A., Noey, E. L., Houk, K. N., Liao, J. C., 2012. Engineering synthetic recursive
477 pathways to generate non-natural small molecules. *Nat. Chem. Biol.* 8, 518-26.
- 478 Gokhale, R. S., Sankaranarayanan, R., Mohanty, D., 2007. Versatility of polyketide synthases in
479 generating metabolic diversity. *Curr. Opin. Struct. Biol.* 17, 736-43.
- 480 Gronenberg, L. S., Marcheschi, R. J., Liao, J. C., 2013. Next generation biofuel engineering in prokaryotes.
481 *Curr. Opin. Chem. Biol.* 17, 462-71.
- 482 Harder, B. J., Bettenbrock, K., Klamt, S., 2018. Temperature-dependent dynamic control of the TCA cycle
483 increases volumetric productivity of itaconic acid production by *Escherichia coli*. *Biotechnol.*
484 *Bioeng.* 115, 156-164.
- 485 Haushalter, R. W., Phelan, R. M., Hoh, K. M., Su, C., Wang, G., Baidoo, E. E. K., Keasling, J. D., 2017.
486 Production of odd-carbon dicarboxylic acids in *Escherichia coli* using an engineered biotin-fatty
487 acid biosynthetic pathway. *J. Am. Chem. Soc.* 139, 4615-4618.
- 488 Hoffmann, S. L., Jungmann, L., Schiefelbein, S., Peyriga, L., Cahoreau, E., Portais, J. C., Becker, J.,
489 Wittmann, C., 2018. Lysine production from the sugar alcohol mannitol: Design of the cell
490 factory *Corynebacterium glutamicum* SEA-3 through integrated analysis and engineering of
491 metabolic pathway fluxes. *Metab Eng.* 47, 475-487.
- 492 Howell, D. M., Graupner, M., Xu, H. M., White, R., 2000. Identification of enzymes homologous to
493 isocitrate dehydrogenase that are involved in coenzyme B and leucine biosynthesis in
494 methanoarchaea. *J. Bacteriol.* 182, 5013-5016.
- 495 Howell, D. M., Harich, K., Xu, H., White, R. H., 1998. α -keto acid chain elongation reactions involved in
496 the biosynthesis of coenzyme B in methanogenic archaea. *Biochemistry.* 37, 10108-10117.
- 497 Hunter, M. F., Parker, E. J., 2014. Modifying the determinants of alpha-ketoacid substrate selectivity in
498 *Mycobacterium tuberculosis* alpha-isopropylmalate synthase. *FEBS Lett.* 588, 1603-7.
- 499 Jantama, K., Haupt, M. J., Svoronos, S. A., Zhang, X., Moore, J. C., Shanmugam, K. T., Ingram, L. O., 2008.
500 Combining metabolic engineering and metabolic evolution to develop nonrecombinant strains
501 of *Escherichia coli* C that produce succinate and malate. *Biotechnol. Bioeng.* 99, 1140-53.
- 502 Job, V., Marcone, G. L., Pilone, M. S., Pollegioni, L., 2002. Glycine oxidase from *Bacillus subtilis*.
503 Characterization of a new flavoprotein. *J. Biol. Chem.* 277, 6985-93.
- 504 Jorge, J. M. P., Perez-Garcia, F., Wendisch, V. F., 2017. A new metabolic route for the fermentative
505 production of 5-aminovalerate from glucose and alternative carbon sources. *Bioresource*
506 *Technol.* 245, 1701-1709.
- 507 Katz, L., Donadio, S., 1993. Polyketide synthesis: prospects for hybrid antibiotics. *Annu. Rev. Microbiol.*
508 47, 875-912.
- 509 Kim, H. T., Baritugo, K. A., Oh, Y. H., Hyun, S. M., Khang, T. U., Kang, K. H., Jung, S. H., Song, B. K., Park,
510 K., Kim, I. K., Lee, M. O., Kam, Y., Hwang, Y. T., Park, S. J., Joo, J. C., 2018. Metabolic Engineering
511 of *Corynebacterium glutamicum* for the High-Level Production of Cadaverine That Can Be Used
512 for the Synthesis of Biopolyamide 510. *ACS Sustainable Chemistry and Engineering.*
- 513 Li, S., Wen, J., Jia, X., 2011. Engineering *Bacillus subtilis* for isobutanol production by heterologous
514 Ehrlich pathway construction and the biosynthetic 2-ketoisovalerate precursor pathway
515 overexpression. *Appl. Microbiol. Biotechnol.* 91, 577-89.
- 516 Li, Z., Xu, J., Jiang, T., Ge, Y., Liu, P., Zhang, M., Su, Z., Gao, C., Ma, C., Xu, P., 2016. Overexpression of
517 transport proteins improves the production of 5-aminovalerate from L-lysine in *Escherichia coli*.
518 *Sci. Rep.* 6, 30884.
- 519 Lu, J., Meng, H. Y., Meng, Z. Y., Sun, Y., Pribis, J. P., Zhu, C. Y., Li, Q., 2015. epsilon aminocaproic acid
520 reduces bloodtransfusion and improves the coagulation test after pediatric. *Int. J. Clin. Exp.*

- 521 Pathol. 8, 7978-7987.
- 522 Marcheschi, R. J., Li, H., Zhang, K., Noey, E. L., Kim, S., Chaubey, A., Houk, K. N., Liao, J. C., 2012. A
523 synthetic recursive "+1" pathway for carbon chain elongation. ACS Chem. Biol. 7, 689-97.
- 524 Mirza, N., Crocoll, C., Erik Olsen, C., Ann Halkier, B., 2016. Engineering of methionine chain elongation
525 part of glucoraphanin pathway in E. coli. Metab Eng. 35, 31-37.
- 526 Miyanaga, A., 2017. Structure and function of polyketide biosynthetic enzymes: various strategies for
527 production of structurally diverse polyketides. Biosci. Biotechnol. Biochem. 81, 2227-2236.
- 528 Muller, M., Katzberg, M., Bertau, M., Hummel, W., 2010. Highly efficient and stereoselective
529 biosynthesis of (2S,5S)-hexanediol with a dehydrogenase from *Saccharomyces cerevisiae*. Org.
530 Biomol. Chem. 8, 1540-50.
- 531 Muramatsu, H., Mihara, H., Yasuda, M., Ueda, M., Kurihara, T., Esaki, N., 2006. Enzymatic synthesis of L-
532 pipercolic acid by Delta1-piperideine-2-carboxylate reductase from *Pseudomonas putida*. Biosci.
533 Biotechnol. Biochem. 70, 2296-8.
- 534 Pang, X., Zhuang, X., Tang, Z., Chen, X., 2010. Polylactic acid (PLA): research, development and
535 industrialization. Biotechnol J. 5, 1125-36.
- 536 Schou-Pedersen, A. M., Cornett, C., Nyberg, N., Ostergaard, J., Hansen, S. H., 2015. Structure elucidation
537 and quantification of impurities formed between 6-aminocaproic acid and the excipients citric
538 acid and sorbitol in an oral solution using high-resolution mass spectrometry and nuclear
539 magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 107, 333-40.
- 540 Sgobba, E., Stumpf, A. K., Vortmann, M., Jagmann, N., Krehenbrink, M., Dirks-Hofmeister, M. E.,
541 Moerschbacher, B., Philipp, B., Wendisch, V. F., 2018. Synthetic *Escherichia coli*-
542 *Corynebacterium glutamicum* consortia for L-lysine production from starch and sucrose.
543 Bioresour Technol. 260, 302-310.
- 544 Shen, C. R., Liao, J. C., 2008. Metabolic engineering of *Escherichia coli* for 1-butanol and 1-propanol
545 production via the keto-acid pathways. Metab Eng. 10, 312-20.
- 546 Shen, C. R., Liao, J. C., 2011. A synthetic iterative pathway for ketoacid elongation. Methods Enzymol.
547 497, 469-81.
- 548 Shin, J. H., Park, S. H., Oh, Y. H., Choi, J. W., Lee, M. H., Cho, J. S., Jeong, K. J., Joo, J. C., Yu, J., Park, S. J.,
549 Lee, S. Y., 2016. Metabolic engineering of *Corynebacterium glutamicum* for enhanced
550 production of 5-aminovaleric acid. Microb Cell Fact. 15, 174.
- 551 Sonderby, I. E., Geu-Flores, F., Halkier, B. A., 2010. Biosynthesis of glucosinolates--gene discovery and
552 beyond. Trends Plant Sci. 15, 283-90.
- 553 Tani, Y., Miyake, R., Yukami, R., Dekishima, Y., China, H., Saito, S., Kawabata, H., Mihara, H., 2015a.
554 Functional expression of L-lysine alpha-oxidase from *Scomber japonicus* in *Escherichia coli* for
555 one-pot synthesis of L-pipercolic acid from DL-lysine. Appl. Microbiol. Biotechnol. 99, 5045-54.
- 556 Tani, Y., Omatsu, K., Saito, S., Miyake, R., Kawabata, H., Ueda, M., Mihara, H., 2015b. Heterologous
557 expression of L-lysine alpha-oxidase from *Scomber japonicus* in *Pichia pastoris* and functional
558 characterization of the recombinant enzyme. J. Biochem. 157, 201-10.
- 559 Textor, S., de Kraker, J. W., Hause, B., Gershenzon, J., Tokuhisa, J. G., 2007. MAM3 catalyzes the formation
560 of all aliphatic glucosinolate chain lengths in *Arabidopsis*. Plant Physiol. 144, 60-71.
- 561 Turk, S. C., Kloosterman, W. P., Ninaber, D. K., Kolen, K. P., Knutova, J., Suir, E., Schurmann, M.,
562 Raemakers-Franken, P. C., Muller, M., de Wildeman, S. M., Raamsdonk, L. M., van der Pol, R.,
563 Wu, L., Temudo, M. F., van der Hoeven, R. A., Akeroyd, M., van der Stoel, R. E., Noorman, H. J.,
564 Bovenberg, R. A., Trefzer, A. C., 2016. Metabolic Engineering toward Sustainable Production of
565 Nylon-6. ACS Synth Biol. 5, 65-73.
- 566 Umbarger, H. E., 1978. Amino acid biosynthesis and its regulation. Ann. Rev. Biochem. 47, 533-606.
- 567 Vassilev, I., Giesselmann, G., Schwechheimer, S. K., Wittmann, C., Viridis, B., Kromer, J. O., 2018. Anodic
568 Electro-Fermentation: Anaerobic production of L-Lysine by recombinant *Corynebacterium*
569 *glutamicum*. Biotechnol. Bioeng. 115, 1499-1508.
- 570 Wang, Y., Li, Q., Zheng, P., Guo, Y., Wang, L., Zhang, T., Sun, J., Ma, Y., 2016. Evolving the L-lysine high-
571 producing strain of *Escherichia coli* using a newly developed high-throughput screening
572 method. J. Ind. Microbiol. Biotechnol. 43, 1227-35.
- 573 Wen, M., Bond-Watts, B. B., Chang, M. C., 2013. Production of advanced biofuels in engineered E. coli.
574 Curr. Opin. Chem. Biol. 17, 472-9.
- 575 Weng, J. K., Noel, J. P., 2012. The remarkable pliability and promiscuity of specialized metabolism. Cold
576 Spring Harb. Symp. Quant. Biol. 77, 309-20.
- 577 Wu, H., Karanjikar, M., San, K. Y., 2014. Metabolic engineering of *Escherichia coli* for efficient free fatty

- 578 acid production from glycerol. *Metab Eng.* 25, 82-91.
- 579 Xiong, M., Deng, J., Woodruff, A. P., Zhu, M., Zhou, J., Park, S. W., Li, H., Fu, Y., Zhang, K., 2012. A bio-
580 catalytic approach to aliphatic ketones. *Sci. Rep.* 2, 311.
- 581 Xu, J. Z., Yang, H. K., Liu, L. M., Wang, Y. Y., Zhang, W. G., 2018. Rational modification of *Corynebacterium*
582 *glutamicum* dihydrodipicolinate reductase to switch the nucleotide-cofactor specificity for
583 increasing l-lysine production. *Biotechnol. Bioeng.* 115, 1764-1777.
- 584 Yang, J. G., Sun, S. S., Men, Y., Zeng, Y., Zhu, Y. M., Sun, Y. X., Ma, Y. H., 2017. Transformation of
585 formaldehyde into functional sugars via multi-enzyme stepwise cascade catalysis. *Catalysis*
586 *Science and Technology.* 1-6.
- 587 Yu, P., Tai, Y.-S., Woodruff, A. P., Xiong, M., Zhang, K., 2012. Engineering artificial metabolic pathways for
588 biosynthesis. *Current Opinion in Chemical Engineering.* 1, 373-379.
- 589 Zabriskie, T. M., Jackson, M. D., 2000. Lysine biosynthesis and metabolism in fungi. *Nat. Prod. Rep.* 17,
590 85-97.
- 591 Zhang, K., Li, H., Cho, K. M., Liao, J. C., 2010. Expanding metabolism for total biosynthesis of the
592 nonnatural amino acid L-homoalanine. *Proc. Natl. Acad. Sci. U. S. A.* 107, 6234-9.
- 593 Zhang, K., Sawaya, M. R., Eisenberg, D. S., Liao, J. C., 2008. Expanding metabolism for biosynthesis of
594 nonnatural alcohols. *Proc. Natl. Acad. Sci. U. S. A.* 105, 20653-8.
- 595 Zheng, G., Jin, W., Fan, P., Feng, X., Bai, Y., Tao, T., Yu, L., 2015. A novel method for detecting amino acids
596 derivatized with phenyl isothiocyanate by high-performance liquid chromatography-
597 electrospray ionization mass spectrometry. *Int J Mass Spectrom.* 392, 1-6.
- 598
- 599

Table 1

Purification of L-lysine α oxidase (RaiP) from *Scomber japonicas* and α -isopropylmalate synthase mutant LeuA[#] (LeuA with H97L/S139G/G462D mutations) expressed in *E. coli*.

Enzyme	Step	Total protein (mg)	Total activity (units)	Specific activity (units/mg)	Purification (fold)	Yield (%)
	Cell extract	310.23±21.84	1595.21±78.52	5.14±0.26	1	100
RaiP	Ni-NTA	1.29±0.09	935.09±65.48	724.88±46.24	141	58.62
	Cell extract	521.51±32.16	0.60±0.01	0.0012±0.0001	1	100
LeuA [#]	Ni-NTA	2.97±0.13	0.08±0.01	0.03±0.002	25	13.33

Data are presented as means \pm STDV calculated from at least three replicates. The RaiP activity was conducted on 50 mM KPb (pH 8.0), 30.0 mM L-lysine, 0.5 mM 4-aminoantipyrine, 10 units/ml catalase and 26.5 mM phenol, 8 μ g RaiP with a total volume of 205 μ L. The reaction was incubated at 30 °C and stopped by adding 10 μ L of 10 M HCl. The quinoneimine dye formed was measured at 505 nm per 5 minutes. The LeuA[#] activity was performed on 50 mM KPb (pH 8.0), 0.03 μ M acetyl-CoA, 30.0 mM L-lysine, 2.0 μ M RaiP and 8 μ g LeuA[#] with a total volume of 205 μ L. The reaction was performed at 37 °C and stopped by adding 10 μ L of 10 M HCl. 50 μ L of a fresh 3.0 mM solution of DTNB in 50 mM KPb was added, and the yellow color product was determined at 412 nm.

Table 2Kinetic parameters of α -isopropylmalate synthase mutants (LeuA*) on 2-keto-6-aminocaproate.

Enzyme	Natural substrate						2-Keto-6-aminocaproate			Specificity ^a	Specificity ^b
	α -Ketoisovalerate			α -Ketobutyrate			V_{max}	K_m (mM)	V_{max}/K_m		
	V_{max} (mMmin ⁻¹)	K_m (mM)	V_{max}/K_m (h ⁻¹)	V_{max} (mMmin ⁻¹)	K_m (mM)	V_{max}/K_m (h ⁻¹)	V_{max} (mMmin ⁻¹)	K_m (mM)	V_{max}/K_m (h ⁻¹)		
LeuA*(H97A/S 139G/G462D)	45.708±4.588	4.359±0.105	629.153	23.366±3.276	6.674±0.388	210.063	0.179±0.005	23.864±3.255	0.475	255.35	130.54
LeuA*(H97A/S 139I/G462D)	48.441±5.265	4.256±0.226	682.909	25.841±3.121	6.245±0.371	248.272	0.120±0.004	24.889±4.269	0.289	403.43	215.34
LeuA*(H97G/S 139G/G462D)	49.625±3.251	4.123±0.345	722.168	28.344±2.866	5.556±0.333	306.091	0.174±0.011	24.013±2.387	0.435	285.20	162.90
LeuA*(H97G/S 139I/G462D)	51.392±3.363	3.959±0.328	778.863	23.653±2.484	6.999±0.412	202.769	0.085±0.003	25.661±5.854	0.199	604.61	278.27
LeuA*(H97L/S 139I/G462D)	53.647±4.125	3.867±0.269	832.382	24.362±2.999	6.114±0.292	239.078	0.140±0.010	24.562±3.412	0.342	383.19	174.01
LeuA*(H97L/S 139G/G462D)	55.699±7.005	3.756±0.274	889.760	30.258±3.687	5.121±0.345	354.517	0.229±0.014	23.450±4.263	0.586	243.23	132.13

^a Specificity of α -isopropylmalate synthase mutants (LeuA*) refers to the specificity of α -ketoisovalerate to 2-keto-6-aminocaproate.^b Specificity of α -isopropylmalate synthase mutants (LeuA*) refers to the specificity of α -ketobutyrate to 2-keto-6-aminocaproate.

Data are presented as means \pm STDV calculated from at least three replicates. The RaiP activity was conducted on 50 mM KPb (pH 8.0), 30.0 mM L-lysine, 0.5 mM 4-aminoantipyrine, 10 units/ml catalase and 26.5 mM phenol, 8 μ g RaiP with a total volume of 205 μ L. The reaction was incubated at 30 °C and stopped by adding 10 μ L of 10 M HCl. The quinoneimine dye formed was measured at 505 nm per 5 minutes. Determination of K_m for L-lysine was performed using various L-lysine concentrations at 30 °C and pH 8.0. The LeuA* activity was performed on 50 mM KPb (pH 8.0), 0.03 μ M acetyl-CoA, 30.0 mM L-lysine, 2.0 μ M RaiP and 8 μ g LeuA[#] with a total volume of 205 μ L. The reaction was performed at 37 °C and stopped by adding 10 μ L of 10 M HCl. 50 μ L of a fresh 3.0 mM solution of DTNB in

50 mM KPB (pH 8.0) was added, and the yellow color product was determined at 412 nm. Determination of K_m for 2-keto-6-Aminocaproate was performed using various 2-keto-6-Aminocaproate concentrations at 37 °C and pH 8.0.

Captions to Figures

Fig. 1. A: Engineered artificial iterative carbon-chain-extension cycle for the production of NNSCAAs. B: Synthetic operons for gene expression. (1) Synthetic operon for protein overexpression to drive the carbon flux towards 2-keto-6-aminocaproate. (2) Synthetic operon carrying mutations of LeuA (LeuA[#]) for protein overexpression to drive the carbon flux towards 2-keto-6-aminocaproate. (3) Synthetic operon for protein overexpression for deaminase, decarboxylase and dehydrogenase. NNSCAAs, Nonnatural straight chain amino acids. RaiP, L-lysine α oxidase; LeuA, α -Isopropylmalate synthase; LeuA*, LeuA mutants; LeuA[#], LeuA with H97L/S139G/G462D mutations; LeuB, 3-Isopropylmalate dehydrogenase; LeuC, 3-Isopropylmalate dehydratase; LeuD, 3-Isopropylmalate dehydratase; KivD, α -Ketoacid decarboxylase; PadA, Phenylacetaldehyde dehydrogenase; ThDP, Thiamine diphosphate.

Fig. 2. Specific activities of various LeuA mutants. The assay mixture contained 50 mM KPB, 0.03 μ M acetyl-CoA and 30.0 mM L-lysine, 2.0 μ M RaiP and 8 μ g LeuA* with a total volume of 205 μ L. All experiments were performed a minimum of three independent sets. All error bars represent standard deviations with $n \geq 3$ independent reactions.

Fig. 3. LC-MS confirmation of NNSCAAs (5AVA, 6ACA, 7AHA) biosynthesis by strain CJ04. A: HPLC results of 5AVA, 6ACA and 7AHA from fermentation broth. B: Mass spectrum of 5AVA from fermentation broth. C: Mass spectrum of 6ACA from fermentation broth. D: Mass spectrum of 7AHA from fermentation broth. Samples were derived with phenyl isothiocyanate (PITC) for LC-MS analysis. Strain CJ04 is the strain BL21(DE3) harboring plasmids pIVC4 and pET21aRKP. 5AVA, 5-Aminovalerate. 6ACA, 6-Aminocaproate. 7AHA, 7-Aminoheptanoate.

Fig. 4. The optimal molar ratio of RaiP:LeuA[#]:LeuB:LeuC:LeuD:KivD:PadA for the production of NNSCAAs. NNSCAAs, Nonnatural straight chain amino acids. 6ACA, 6-Aminocaproate. All experiments were performed a minimum of three independent sets. All error bars represent standard deviations with $n \geq 3$ independent reactions.

Fig. 5. Coenzymes optimizations lead to increased yields of NNSCAAs production. A: Reactions for NNSCAAs production from L-lysine were performed using different sets of NAD⁺. Each assay mixture included 2.0 mM acetyl-CoA, 1.0 μ M RaiP, 20.0 μ M LeuA[#], 4.0 μ M LeuB, 2.0 μ M LeuC, 2.0 μ M LeuD, 5.0 μ M KivD, 2.0 μ M PadA, 2.5 mM L-lysine, 1.0 mM MgCl₂, 1.0 mM TCEP, 0.5 mM ThDP, and varying concentrations of NAD⁺. Reactions incubated for 8 h at 37 °C. B: Reactions for NNSCAAs production from L-lysine were performed using different sets of ThDP. Each assay mixture included 2.0 mM acetyl-CoA, 1.0 μ M RaiP, 20.0 μ M LeuA[#], 4.0 μ M LeuB, 2.0 μ M LeuC, 2.0 μ M LeuD, 5.0 μ M KivD, 2.0 μ M PadA, 2.5 mM L-lysine, 1.0 mM MgCl₂, 1.0 mM TCEP, 1.0 mM ThDP, and varying concentrations of ThDP. Reactions incubated for 8 h at 37 °C. 6ACA, 6-Aminocaproate. 7AHA, 7-Aminoheptanoate. All experiments were performed a minimum of three independent sets. All error bars represent standard deviations with $n \geq 3$ independent reactions.

Fig. 6. Biosynthesis of NNSCAAs achieved via an artificial iterative carbon-chain-extension cycle. A: Iterative carbon-chain-extension cycle reactions for NNSCAAs production from L-lysine were carried out using seven purified enzymes mixed together (1:20:4:2:2:5:2 based on purified protein quantification) with 1.0 mM MgCl₂, 1.0 mM TCEP, 50 mM KPB, and coenzymes (ThDP, NAD⁺). These purified enzymes individually contained RaiP, LeuA[#], LeuB, LeuC, LeuD, KivD and PadA selectively overexpressed at 20 °C. B: RCCEC reactions for NNSCAAs production from L-lysine were carried out using seven crude lysates mixed together (1:20:4:2:2:5:2 based on total protein quantification) with 1.0 mM MgCl₂, 1.0 mM TCEP, 50 mM KPB, and coenzymes (ThDP, NAD⁺). These lysates individually contained RaiP, LeuA[#], LeuB, LeuC, LeuD, KivD and PadA selectively overexpressed at 20 °C. NNSCAAs, Nonnatural straight chain amino acids. 5AVA, 5-Aminovalerate. 6ACA, 6-Aminocaproate. 7AHA, 7-Aminoheptanoate. All experiments were performed a minimum of three independent sets. All error bars represent standard deviations with n ≥ 3 independent reactions.

Fig. 7. NNSCAAs synthesis by engineered strain CJ04 in 250 mL flask. The cells were grown in 40 mL LB supplemented with 100 µg/mL ampicillin, 50 µg/mL kanamycin, 0.5 mM of IPTG, 5 g/L L-lysine, 1.0 mM MgSO₄ and 0.5 mM ThDP at 37 °C with 250 RPM orbital shaking. Strain CJ04 is strain BL21(DE3) plus plasmids pIVC4 and pET21aRKP. NNSCAAs, Nonnatural straight chain amino acids. 5AVA, 5-Aminovalerate. 6ACA, 6-Aminocaproate. 7AHA, 7-Aminoheptanoate. All experiments were performed a minimum of three independent sets. All error bars represent standard deviations with n ≥ 3 independent reactions.





Fig. 1






Fig. 2







Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7